中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2015年
4期
458-460
,共3页
CYP2C19基因多态性%血栓弹力图%氯吡格雷低反应%抗血小板治疗
CYP2C19基因多態性%血栓彈力圖%氯吡格雷低反應%抗血小闆治療
CYP2C19기인다태성%혈전탄력도%록필격뢰저반응%항혈소판치료
CYP2C19 gene polymorphism%Thrombelastogram%Low clopidogrel response%Antiplatelet therapy
目的：探讨CYP2C19基因多态性与氯吡格雷低反应（LCR）发生率的关系。方法选择2014年1月至2015年1月成功接受经皮冠状动脉介入治疗，同时进行CYP2C19基因多态性和血栓弹力图检查的冠心病患者205例，根据是否携带CYP2C19功能缺失等位基因分为功能缺失等位基因组（LOF）和非功能缺失等位基因组（no-LOF）两组，比较两组患者的临床资料（一般情况、合并疾病、合并用药）和氯吡格雷对血小板聚集抑制率。结果纳入患者中CYP2C19功能缺失等位基因的发生率为60.0%。LOF与no-LOF两组患者的一般情况、合并疾病、合并用药的比较，差异均无统计学意义（P均＞0.05）。LOF组血栓弹力图提示氯吡格雷低反应（LCR）的发生率为53.6%，高于no-LOF组LCR的发生率（45.1%），但两组患者氯吡格雷LCR发生率无统计学差异（χ2=1.434，P＞0.05）。结论 CYP2C19功能缺失等位基因患者LCR发生率稍高于CYP2C19非功能缺失等位基因组，但未发现统计学差异。
目的：探討CYP2C19基因多態性與氯吡格雷低反應（LCR）髮生率的關繫。方法選擇2014年1月至2015年1月成功接受經皮冠狀動脈介入治療，同時進行CYP2C19基因多態性和血栓彈力圖檢查的冠心病患者205例，根據是否攜帶CYP2C19功能缺失等位基因分為功能缺失等位基因組（LOF）和非功能缺失等位基因組（no-LOF）兩組，比較兩組患者的臨床資料（一般情況、閤併疾病、閤併用藥）和氯吡格雷對血小闆聚集抑製率。結果納入患者中CYP2C19功能缺失等位基因的髮生率為60.0%。LOF與no-LOF兩組患者的一般情況、閤併疾病、閤併用藥的比較，差異均無統計學意義（P均＞0.05）。LOF組血栓彈力圖提示氯吡格雷低反應（LCR）的髮生率為53.6%，高于no-LOF組LCR的髮生率（45.1%），但兩組患者氯吡格雷LCR髮生率無統計學差異（χ2=1.434，P＞0.05）。結論 CYP2C19功能缺失等位基因患者LCR髮生率稍高于CYP2C19非功能缺失等位基因組，但未髮現統計學差異。
목적：탐토CYP2C19기인다태성여록필격뢰저반응（LCR）발생솔적관계。방법선택2014년1월지2015년1월성공접수경피관상동맥개입치료，동시진행CYP2C19기인다태성화혈전탄력도검사적관심병환자205례，근거시부휴대CYP2C19공능결실등위기인분위공능결실등위기인조（LOF）화비공능결실등위기인조（no-LOF）량조，비교량조환자적림상자료（일반정황、합병질병、합병용약）화록필격뢰대혈소판취집억제솔。결과납입환자중CYP2C19공능결실등위기인적발생솔위60.0%。LOF여no-LOF량조환자적일반정황、합병질병、합병용약적비교，차이균무통계학의의（P균＞0.05）。LOF조혈전탄력도제시록필격뢰저반응（LCR）적발생솔위53.6%，고우no-LOF조LCR적발생솔（45.1%），단량조환자록필격뢰LCR발생솔무통계학차이（χ2=1.434，P＞0.05）。결론 CYP2C19공능결실등위기인환자LCR발생솔초고우CYP2C19비공능결실등위기인조，단미발현통계학차이。
Objective To study the relationship between CYP2C19 gene polymorphism and incidence of low clopidogrel response (LCR). Methods The patients (n=205) undergone successful PCI and examinations of CYP2C19 gene polymorphism and thrombelastogram (TEG) were chosen from Jan. 2014 to Jan. 2015, and divided, according to whether or not carrying CYP2C19 loss-of-the function (LOF) allele, into LOF group and no-LOF group. The clinical data (general conditions, complications and combined medication) and inhibitory rate of platelet aggregation of clopidogrel were compared between 2 groups. Results The incidence of CYP2C19 LOF allele was 60.0%in all patients. The comparison in general conditions, complications and combined medication showed the difference was not statistically significant between 2 groups (all P>0.05). The outcomes of TEG showed that incidence of LCR was 53.6%in LOF group and 45.1%in no-LOF group, and difference was not statistically significant between 2 groups (χ2=1.434, P>0.05). Conclusion The incidence of LCR is slightly higher in patients with CYP2C19 LOF allele than that in those without CYP2C19 LOF allele but there is no statistical difference.
